Agilent Technologies (A) 58.25 $A
Research and Markets: Global PCR Technologies Global Market 2014-2020
Business Wire - 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rb5tts/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering.
Global PCR Technologies Global Market 2014-2020
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/4kvrrv/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering. Some of the key players in the PCR market are Abbott Laboratories, Affymetrix, inc., Takara bio, Agilent Technologies, Beckman Coulter Inc., Quanta biosciences, Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp., and Roche. Polymerase chain reaction (PCR) is a gene amplification technique that amplifies a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. PCR plays a crucial role in understanding the genetic diseases and is also used in the characterization and detection of infectious disease organisms in diseases like Lyme disease, AIDS, middle ear infection and tuberculosis. PCR is an indispensable technique in Biotechnology, drug discovery and clinical diagnostics and it's key applications include DNA sequencing, Forensic science, Genotyping, Bioinformatics, gene expression, genetic mapping and DNA cloning. PCR products market includes Reagents, consumables, instruments, software and services. Some of the key techniques available in market are Standard/basic PCR, Real-time/Q-PCR, Digital PCR (dPCR), Reverse transcriptase PCR, Assembly PCR, Inverse PCR, Nested PCR, Multiplex PCR, Hot start PCR and touchdown PCR Among the various techniques, Q-PCR appears to be the fastest growing in PCR market followed by Reverse-Transcription PCR (RT-PCR) and Assembly. Based on the classification by products/tools, PCR Reagents is expected to be fastest growing PCR market followed by PCR Consumables and Machines. The global PCR market is projected to grow at a healthy rate. North America would account for the largest market share followed by Europe and Asia-pacific. Increasing number of patients suffering from Infectious diseases, Cancers and positive investments in gene therapy and human genome project are further driving the growth of the PCR market. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 PCR Market by Types 5 PCR Market by Application 6 PCR Market by Technology 7 Regional Market Analysis 8 Company Developments 9 Major Company Profiles - Abbott Laboratories - Becton, Dickinson And Co. - Bio-Rad - Ge Healthcare - Kapa Biosystems - Maxim Biotech - Promega Corp. - Quanta Biosciences Inc. - Roche - Sigma-Aldrich Corp. - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/4k...chnologies
Agilent Technologies Calls for Partial Redemption of Outstanding 6.5 Percent Senior Notes Due November 2017
Business Wire - Fri Sep 19, 3:05PM CDT
Agilent Technologies Inc. (NYSE:A) today announced it will redeem $500 million of $600 million outstanding 6.50 percent senior notes due November 2017 on Oct. 20, 2014, the redemption date. This decision is consistent with Agilent's intention to resize its debt portfolio in connection with the expected spinoff of Keysight Technologies.
Charles Dockendorff to Join Keysight Technologies Board of Directors
Business Wire - Fri Sep 19, 10:00AM CDT
Keysight Technologies, Inc., the spinoff electronic measurement company of Agilent Technologies, today announced plans to appoint Charles J. Dockendorff to its board of directors.
How Will Agilent Technologies (A) Stock Be Affected By Its CEO Transition?
at The Street - Thu Sep 18, 11:01AM CDT
Agilent Technologies (A) announced that Mike McMullen will take over as CEO from William Sullivan next March.
Agilent Board Backs Keysight Spinoff, to Pay Stock Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:40AM CDT
The board of directors of Agilent (A) has consented to the spinoff of its electronic measurement subsidiary Keysight and that that Keysight's outstanding common stock would be distributed to Agilent's shareholders as a special dividend distribution.
Agilent Technologies Set to Possibly Pullback After Yesterday's Rally of 1.69%
Comtex SmarTrend(R) - Wed Sep 17, 5:12PM CDT
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $57.92 to a high of $58.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $58.63 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Agilent Technologies to Potentially Pullback After Gaining 1.69% Yesterday
Comtex SmarTrend(R) - Wed Sep 17, 5:11PM CDT
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $57.92 to a high of $58.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $58.63 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Agilent Technologies Board of Directors Approves Separation of Keysight, Declares Special Dividend Distribution of Keysight Stock
Business Wire - Wed Sep 17, 3:58PM CDT
Agilent Technologies Inc. (NYSE: A) announced today that its board of directors has approved the separation of its electronic measurement subsidiary, Keysight Technologies Inc., and declared a special dividend distribution of all outstanding shares of Keysight's common stock to Agilent's shareholders.
Agilent Technologies Creates New Group for Services and Consumables
Business Wire - Wed Sep 17, 3:56PM CDT
Agilent Technologies Inc. (NYSE: A) today announced it has created a new services and consumables organization, the Agilent CrossLab Group, and named Mark Doak group president, effectively immediately. Doak has been senior vice president and general manager of the Services and Support Division.
Agilent Technologies Announces CEO Transition: Mike McMullen to Succeed Bill Sullivan in March 2015
Business Wire - Wed Sep 17, 3:54PM CDT
Agilent Technologies Inc. (NYSE:A) today announced that Mike McMullen, senior vice president, Agilent, and president of the company's Chemical Analysis Group (CAG), will succeed William (Bill) Sullivan as CEO on March 18, 2015. Sullivan will remain as an advisor through the end of the company's fiscal year, Oct. 31, 2015, when he will retire.
World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com
PRWeb - Wed Sep 17, 1:01PM CDT
The in vitro diagnostics (IVD) marketplace is a subset of the total medical technology market, focusing on molecular diagnostics for conditions such as infectious diseases, sexually-transmitted diseases, cancer, chronic diseases, and genetic testing. The IVD market value is projected to be worth around USD 70 billion by the end of 2017. The major drivers of the market's growth include the shift to point-of-care testing; need for speed, which is evidenced by the explosion for raid and minimally-invasive diagnostic tools; demand from emerging markets; and ageing population in a lot of countries. Roche Diagnostics, Siemens Healthcare, Abbot Laboratories, Agilent Technologies, diaDexus, among others, are the prominent players in the market.
Global Bioinformatics Market Outlook 2019
M2 - Wed Sep 17, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xtd5rk/global) has announced the addition of the "Global Bioinformatics Market Outlook 2019" report to their offering. The global bioinformatics market reached the mark of around US$ 3.7 Billion in 2013 with the anticipation of its growth at a CAGR of around 19% during 2015-2019 The report is an outcome of an in-depth research and comprehensive analysis of global developments and opportunities listed in the section of the bioinformatics trends. The bioinformatics market essentially is divided into 3 sections for a categorical study of the industry viz. by segment, by application and by region. By segment, the bioinformatics market is divided into data analysis and software, tools and database services, and IT Infrastructure. Accordingly, the report provides a comprehensive analysis of each of these segments coupled with the information on key software and databases popular in the industry. In the application area of the bioinformatics industry, the report covers various aspects of the global bioinformatics market, giving detailed analysis of its various applications, including genomics, proteomics, transcriptomics, cheminformatics, metabolomics and molecular phylogenetics, covering the sizes of the bioinformatics market for each of these application areas till 2019. The report also offers a geographical picture of the bioinformatics sector in four regions viz. North America, Europe, Asia-Pacific and Latin America. Additionally, through country level analysis, the report portrays the bioinformatics market in major countries like US, UK, South Korea, India etc., to understand their individual market growth and future directions. A competitive analysis in the report has been done with an assortment of all the major bioinformatics players that have been active in the research and development of bioinformatics products and services. It encloses the overview, key financials and strategic initiatives by the players. In a nutshell, the research provides all the prerequisite information for intending clients looking out to venture into this industry and facilitates them to devise strategies, while going for an investment/partnership in the global bioinformatics market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Key Industry Trends and Drivers 4. Bioinformatics Market Outlook to 2019 5. Country Level Analysis 6. Commercialized Products and Services 7. Key Players - Biodiscovery, Inc. - Geneva Bioinformatics (Genebio) SA - Kinexus Bioinformatics Corporation - Accelrys, Inc. - Affymetrix, Inc. - Agilent Technologies, Inc. - CLC Bio A/S - Genologics Life Sciences Software, Inc - ID Business Solutions Ltd - Illumina Inc. - Life Technologies Corporation - NonLinear Dynamics Ltd. For more information visit http://www.researchandmarkets.com/research/xtd5rk/global
Global Calibration Services Market
PR Newswire - Tue Sep 16, 4:13PM CDT
This report analyzes the worldwide markets for Calibration Services in US$ Thousands by the following Parameters of Calibration: Mechanical Calibration Services, Electrical Calibration Services, Physical/Dimensional Calibration Services, and Thermodynamic Calibration Services. The End-Use Sectors also analyzed in the report include Electronic Manufacturing, Communication, Aerospace & Defence, Industrial & Automotive, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 148 companies including many key and niche players such as -
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
TRADE NEWS: Keysight Technologies Introduces Industry's First Signal Analyzer to Provide Swept and FFT Capabilities in PXI Form
Business Wire - Tue Sep 16, 10:00AM CDT
Keysight Technologies, Inc. today announced the industry's first signal analyzer to provide swept and FFT-based capabilities in the PXI form factor. The Keysight M9290A CXA-m PXIe signal analyzer delivers fully specified performance up to 26.5 GHz and provides best-in-class specifications in key areas such as sensitivity and dynamic range.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
New Born Screening Market to 2019 - Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit Analysis
M2 - Tue Sep 16, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ntwf6k/newborn_screening) has announced the addition of the "NewBorn Screening Market by Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019" report to their offering. The global newborn screening market, estimated at $438.9 million in 2013, is expected to reach $819.6 million by 2019, growing at a CAGR of 11.0% from 2013 to 2019. The market is segmented on the basis of types, technologies, products, and geography. Based on types, the newborn screening market is segmented into dry blood spot test, hearing screen test, and pulse oximetry test. The dry blood spot test market is slated to grow at the highest CAGR owing to the technological advancements due to which new and advanced products are being launched in the market. Based on technologies, the market is subdivided into tandem mass spectroscopy, electrophoresis, enzyme and immunoassays, DNA-based assays, hearing screen technology, and pulse oximetry. The tandem mass spectroscopy market is expected to witness the highest growth. This high growth can be attributed to time-effectiveness and cost effectiveness provided by mass spectrometry as compared to the enzyme assays and immunoassays technology. These advantages are the major reasons for the growth of this market. The newborn screening products market includes instruments, reagents, and assay kits. The instruments market accounts for the largest share of the global products market, followed by reagents and assay kits. The high share of the instruments market can be attributed to the wide usage of newborn screening devices across the globe. Scope of the Report By Test Type - Dry Blood Spot Test - Hearing Screen Test - Critical Congenital Heart Disease (CCHD) Test By Technology - Tandem Mass Spectrometry - Electrophoresis - Enzymes and Immunoassays - DNA-based Assays - Hearing Screen Technology - Pulse Oximetry Technology By Product - Instruments - Newborn Disorder Screening Instruments - Hearing Screening Instruments - Hearing Screening Devices - Hearing Screening Accessories - Pulse Oximetry Instruments - Reagents and Assay Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Newborn Screening Market, By Test Type 6 Newborn Screening Market, By Technology 7 Newborn Screening Market, By Product Type 8 Newborn Screening Market, By Geography 9 Competitive Landscape 10 Company Profiles - AB Sciex LLC (A Subsidiary of Danaher Corporation) - Agilent Technologies Inc. - Bio-Rad Laboratories, Inc. - Covidien Plc - GE Healthcare (Subsidiary of General Electric Company) - Masimo Corporation - Natus Medical Incorporated - Perkinelmer, Inc. - Trivitron Healthcare - Waters Corporation For more information visit http://www.researchandmarkets.com/research/nt..._screening
Agilent Gets Baa2 Rating from Moody's with Stable Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:40PM CDT
Agilent (A) was recently assigned a Baa2 rating by leading credit rating agency Moody's along with a stable outlook.
Danaher Buying Swiss Dental Firm For $2.2 Billion
at Investor's Business Daily - Mon Sep 15, 10:10AM CDT
Electronic-instrument giant Danaher (DHR) said Monday it's buying Swiss dental-equipment maker Nobel Biocare for $2.2 billion in cash, ending weeks of rumors. The highly diversified Danaher already has a business in high-tech dental gear, which the...
Research and Markets: Global PCR Technologies Global Market 2014-2020
Business Wire - 33 mins ago
Research and Markets (http://www.researchandmarkets.com/research/rb5tts/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering.
Global PCR Technologies Global Market 2014-2020
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/4kvrrv/pcr_technologies) has announced the addition of the "PCR Technologies Global market - Forecast to 2020" report to their offering. Some of the key players in the PCR market are Abbott Laboratories, Affymetrix, inc., Takara bio, Agilent Technologies, Beckman Coulter Inc., Quanta biosciences, Bio-Rad, Becton, Dickinson and Co., GE Healthcare, Sigma-Aldrich Corp., and Roche. Polymerase chain reaction (PCR) is a gene amplification technique that amplifies a single or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence. PCR plays a crucial role in understanding the genetic diseases and is also used in the characterization and detection of infectious disease organisms in diseases like Lyme disease, AIDS, middle ear infection and tuberculosis. PCR is an indispensable technique in Biotechnology, drug discovery and clinical diagnostics and it's key applications include DNA sequencing, Forensic science, Genotyping, Bioinformatics, gene expression, genetic mapping and DNA cloning. PCR products market includes Reagents, consumables, instruments, software and services. Some of the key techniques available in market are Standard/basic PCR, Real-time/Q-PCR, Digital PCR (dPCR), Reverse transcriptase PCR, Assembly PCR, Inverse PCR, Nested PCR, Multiplex PCR, Hot start PCR and touchdown PCR Among the various techniques, Q-PCR appears to be the fastest growing in PCR market followed by Reverse-Transcription PCR (RT-PCR) and Assembly. Based on the classification by products/tools, PCR Reagents is expected to be fastest growing PCR market followed by PCR Consumables and Machines. The global PCR market is projected to grow at a healthy rate. North America would account for the largest market share followed by Europe and Asia-pacific. Increasing number of patients suffering from Infectious diseases, Cancers and positive investments in gene therapy and human genome project are further driving the growth of the PCR market. Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 PCR Market by Types 5 PCR Market by Application 6 PCR Market by Technology 7 Regional Market Analysis 8 Company Developments 9 Major Company Profiles - Abbott Laboratories - Becton, Dickinson And Co. - Bio-Rad - Ge Healthcare - Kapa Biosystems - Maxim Biotech - Promega Corp. - Quanta Biosciences Inc. - Roche - Sigma-Aldrich Corp. - Takara Bio - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/4k...chnologies
Agilent Technologies Calls for Partial Redemption of Outstanding 6.5 Percent Senior Notes Due November 2017
Business Wire - Fri Sep 19, 3:05PM CDT
Agilent Technologies Inc. (NYSE:A) today announced it will redeem $500 million of $600 million outstanding 6.50 percent senior notes due November 2017 on Oct. 20, 2014, the redemption date. This decision is consistent with Agilent's intention to resize its debt portfolio in connection with the expected spinoff of Keysight Technologies.
Charles Dockendorff to Join Keysight Technologies Board of Directors
Business Wire - Fri Sep 19, 10:00AM CDT
Keysight Technologies, Inc., the spinoff electronic measurement company of Agilent Technologies, today announced plans to appoint Charles J. Dockendorff to its board of directors.
How Will Agilent Technologies (A) Stock Be Affected By Its CEO Transition?
at The Street - Thu Sep 18, 11:01AM CDT
Agilent Technologies (A) announced that Mike McMullen will take over as CEO from William Sullivan next March.
Agilent Board Backs Keysight Spinoff, to Pay Stock Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:40AM CDT
The board of directors of Agilent (A) has consented to the spinoff of its electronic measurement subsidiary Keysight and that that Keysight's outstanding common stock would be distributed to Agilent's shareholders as a special dividend distribution.
Agilent Technologies Set to Possibly Pullback After Yesterday's Rally of 1.69%
Comtex SmarTrend(R) - Wed Sep 17, 5:12PM CDT
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $57.92 to a high of $58.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $58.63 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Agilent Technologies to Potentially Pullback After Gaining 1.69% Yesterday
Comtex SmarTrend(R) - Wed Sep 17, 5:11PM CDT
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $57.92 to a high of $58.99. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $58.63 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Agilent Technologies Board of Directors Approves Separation of Keysight, Declares Special Dividend Distribution of Keysight Stock
Business Wire - Wed Sep 17, 3:58PM CDT
Agilent Technologies Inc. (NYSE: A) announced today that its board of directors has approved the separation of its electronic measurement subsidiary, Keysight Technologies Inc., and declared a special dividend distribution of all outstanding shares of Keysight's common stock to Agilent's shareholders.
Agilent Technologies Creates New Group for Services and Consumables
Business Wire - Wed Sep 17, 3:56PM CDT
Agilent Technologies Inc. (NYSE: A) today announced it has created a new services and consumables organization, the Agilent CrossLab Group, and named Mark Doak group president, effectively immediately. Doak has been senior vice president and general manager of the Services and Support Division.
Agilent Technologies Announces CEO Transition: Mike McMullen to Succeed Bill Sullivan in March 2015
Business Wire - Wed Sep 17, 3:54PM CDT
Agilent Technologies Inc. (NYSE:A) today announced that Mike McMullen, senior vice president, Agilent, and president of the company's Chemical Analysis Group (CAG), will succeed William (Bill) Sullivan as CEO on March 18, 2015. Sullivan will remain as an advisor through the end of the company's fiscal year, Oct. 31, 2015, when he will retire.
World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com
PRWeb - Wed Sep 17, 1:01PM CDT
The in vitro diagnostics (IVD) marketplace is a subset of the total medical technology market, focusing on molecular diagnostics for conditions such as infectious diseases, sexually-transmitted diseases, cancer, chronic diseases, and genetic testing. The IVD market value is projected to be worth around USD 70 billion by the end of 2017. The major drivers of the market's growth include the shift to point-of-care testing; need for speed, which is evidenced by the explosion for raid and minimally-invasive diagnostic tools; demand from emerging markets; and ageing population in a lot of countries. Roche Diagnostics, Siemens Healthcare, Abbot Laboratories, Agilent Technologies, diaDexus, among others, are the prominent players in the market.
Global Bioinformatics Market Outlook 2019
M2 - Wed Sep 17, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xtd5rk/global) has announced the addition of the "Global Bioinformatics Market Outlook 2019" report to their offering. The global bioinformatics market reached the mark of around US$ 3.7 Billion in 2013 with the anticipation of its growth at a CAGR of around 19% during 2015-2019 The report is an outcome of an in-depth research and comprehensive analysis of global developments and opportunities listed in the section of the bioinformatics trends. The bioinformatics market essentially is divided into 3 sections for a categorical study of the industry viz. by segment, by application and by region. By segment, the bioinformatics market is divided into data analysis and software, tools and database services, and IT Infrastructure. Accordingly, the report provides a comprehensive analysis of each of these segments coupled with the information on key software and databases popular in the industry. In the application area of the bioinformatics industry, the report covers various aspects of the global bioinformatics market, giving detailed analysis of its various applications, including genomics, proteomics, transcriptomics, cheminformatics, metabolomics and molecular phylogenetics, covering the sizes of the bioinformatics market for each of these application areas till 2019. The report also offers a geographical picture of the bioinformatics sector in four regions viz. North America, Europe, Asia-Pacific and Latin America. Additionally, through country level analysis, the report portrays the bioinformatics market in major countries like US, UK, South Korea, India etc., to understand their individual market growth and future directions. A competitive analysis in the report has been done with an assortment of all the major bioinformatics players that have been active in the research and development of bioinformatics products and services. It encloses the overview, key financials and strategic initiatives by the players. In a nutshell, the research provides all the prerequisite information for intending clients looking out to venture into this industry and facilitates them to devise strategies, while going for an investment/partnership in the global bioinformatics market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Key Industry Trends and Drivers 4. Bioinformatics Market Outlook to 2019 5. Country Level Analysis 6. Commercialized Products and Services 7. Key Players - Biodiscovery, Inc. - Geneva Bioinformatics (Genebio) SA - Kinexus Bioinformatics Corporation - Accelrys, Inc. - Affymetrix, Inc. - Agilent Technologies, Inc. - CLC Bio A/S - Genologics Life Sciences Software, Inc - ID Business Solutions Ltd - Illumina Inc. - Life Technologies Corporation - NonLinear Dynamics Ltd. For more information visit http://www.researchandmarkets.com/research/xtd5rk/global
Global Calibration Services Market
PR Newswire - Tue Sep 16, 4:13PM CDT
This report analyzes the worldwide markets for Calibration Services in US$ Thousands by the following Parameters of Calibration: Mechanical Calibration Services, Electrical Calibration Services, Physical/Dimensional Calibration Services, and Thermodynamic Calibration Services. The End-Use Sectors also analyzed in the report include Electronic Manufacturing, Communication, Aerospace & Defence, Industrial & Automotive, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 148 companies including many key and niche players such as -
Research and Markets: Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
Business Wire - Tue Sep 16, 10:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rcg9gj/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering.
TRADE NEWS: Keysight Technologies Introduces Industry's First Signal Analyzer to Provide Swept and FFT Capabilities in PXI Form
Business Wire - Tue Sep 16, 10:00AM CDT
Keysight Technologies, Inc. today announced the industry's first signal analyzer to provide swept and FFT-based capabilities in the PXI form factor. The Keysight M9290A CXA-m PXIe signal analyzer delivers fully specified performance up to 26.5 GHz and provides best-in-class specifications in key areas such as sensitivity and dynamic range.
Global Companion Diagnostics Market 2014-2019: Roche Diagnostics, Abbott Laboratories, Agilent Technologies, QIAGEN N.V. & Thermo Fisher Scientific Dominate with 86% Market Share
M2 - Tue Sep 16, 9:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8dnfmg/companion) has announced the addition of the "Companion Diagnostics Market byTechnology, Application , & by End-user - Global Trends & Forecasts to 2019" report to their offering. The global companion diagnostics market is expected to reach $8,730.7 million by 2019 from $3,136.9 million in 2014, growing at a CAGR of 22.7% during the forecast period (2014 to 2019). This market is segmented by technology, application, and end user. Technologies are further subsegmented into immunohistochemistry, in situ hybridization (fluoroscent ISH and chromogenic ISH), polymerase chain reaction (PCR), and next-generation sequencing (NGS)-based tests. The application market is further subsegmented into breast cancer, lung cancer, melanoma cancer, and colorectal cancer. The end users are majorly segmented into pharmaceutical companies and reference laboratories. Among technologies, the polymerase chain reaction (PCR)-based test accounted for the largest share of 65.5% in 2013. The growth of companion diagnostic in the other application segments (neurological diseases, infectious diseases, ovarian cancer, and leukemia) is expected to grow at a CAGR of 30.3%; whereas, on the basis of end user, reference laboratories is expected to grow at the fastest rate in the market. The major application driving the global companion diagnostics market is the adoption of companion diagnostic tests in oncology for various indications and for target therapies. Currently, breast, lung colorectal, and melanoma are the major types of cancer for which FDA approved companion diagnostics are available. In addition, encouragement by regulatory bodies and acceptance of tests by end users are the prominent factors for growth of market. Notable restraining factors include varied reimbursement procedures in different regions and usage of non-validated tests for identification of biomarkers. However, advanced technologies such as next-generation sequencing and growth of companion diagnostic in prostate cancer, leukemia, ovarian cancer, Alzheimer's disease, and Parkinson's disease are likely to augment the global companion diagnostic market in the future. In 2013, Roche Diagnostics (Switzerland), Abbott Laboratories (U.S.), Agilent Technologies (U.S.), QIAGEN N.V. (Netherlands), and Thermo Fisher Scientific Inc. (U.S.) together accounted for a share of 86% of the global companion diagnostics market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Global Companion Diagnostics Market, By Applications 8 Global Companion Diagnostics Market, By Technology 9 Market, By End User 10 Global Companion Diagnostics Market, By Geography 11 Competitive Landscape 12 Company Profiles - Abbott Laboratories, Inc. - Agilent Technologies, Inc. - Biogenex Laboratories - Biom?rieux - Danaher Corporation - Ge Healthcare - Myriad Genetics, Inc. - Qiagen N.V. - Roche Diagnostics - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/8dnfmg/companion
New Born Screening Market to 2019 - Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit Analysis
M2 - Tue Sep 16, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ntwf6k/newborn_screening) has announced the addition of the "NewBorn Screening Market by Test Type, Technology, Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019" report to their offering. The global newborn screening market, estimated at $438.9 million in 2013, is expected to reach $819.6 million by 2019, growing at a CAGR of 11.0% from 2013 to 2019. The market is segmented on the basis of types, technologies, products, and geography. Based on types, the newborn screening market is segmented into dry blood spot test, hearing screen test, and pulse oximetry test. The dry blood spot test market is slated to grow at the highest CAGR owing to the technological advancements due to which new and advanced products are being launched in the market. Based on technologies, the market is subdivided into tandem mass spectroscopy, electrophoresis, enzyme and immunoassays, DNA-based assays, hearing screen technology, and pulse oximetry. The tandem mass spectroscopy market is expected to witness the highest growth. This high growth can be attributed to time-effectiveness and cost effectiveness provided by mass spectrometry as compared to the enzyme assays and immunoassays technology. These advantages are the major reasons for the growth of this market. The newborn screening products market includes instruments, reagents, and assay kits. The instruments market accounts for the largest share of the global products market, followed by reagents and assay kits. The high share of the instruments market can be attributed to the wide usage of newborn screening devices across the globe. Scope of the Report By Test Type - Dry Blood Spot Test - Hearing Screen Test - Critical Congenital Heart Disease (CCHD) Test By Technology - Tandem Mass Spectrometry - Electrophoresis - Enzymes and Immunoassays - DNA-based Assays - Hearing Screen Technology - Pulse Oximetry Technology By Product - Instruments - Newborn Disorder Screening Instruments - Hearing Screening Instruments - Hearing Screening Devices - Hearing Screening Accessories - Pulse Oximetry Instruments - Reagents and Assay Kits Key Topics Covered: 1 Introduction 2 Executive Summary 3 Premium Insights 4 Market Overview 5 Newborn Screening Market, By Test Type 6 Newborn Screening Market, By Technology 7 Newborn Screening Market, By Product Type 8 Newborn Screening Market, By Geography 9 Competitive Landscape 10 Company Profiles - AB Sciex LLC (A Subsidiary of Danaher Corporation) - Agilent Technologies Inc. - Bio-Rad Laboratories, Inc. - Covidien Plc - GE Healthcare (Subsidiary of General Electric Company) - Masimo Corporation - Natus Medical Incorporated - Perkinelmer, Inc. - Trivitron Healthcare - Waters Corporation For more information visit http://www.researchandmarkets.com/research/nt..._screening
Agilent Gets Baa2 Rating from Moody's with Stable Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 4:40PM CDT
Agilent (A) was recently assigned a Baa2 rating by leading credit rating agency Moody's along with a stable outlook.
Danaher Buying Swiss Dental Firm For $2.2 Billion
at Investor's Business Daily - Mon Sep 15, 10:10AM CDT
Electronic-instrument giant Danaher (DHR) said Monday it's buying Swiss dental-equipment maker Nobel Biocare for $2.2 billion in cash, ending weeks of rumors. The highly diversified Danaher already has a business in high-tech dental gear, which the...
